Lynch syndrome: History, causes, diagnosis, treatment and prevention (CAPP2 trial)

Digestive Diseases

Volumn 30, Issue SUPPL.2, 2012, Pages 39-47

  Burn, John ^a   Mathers, John ^a   Bishop, D Tim ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Colorectal cancer; Lynch syndrome; Mismatch repair gene

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; DNA; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PLACEBO; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; STARCH;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RISK; CHEMOPROPHYLAXIS; COLONOSCOPY; CONFERENCE PAPER; DNA STRUCTURE; FAMILY HISTORY; FRAMESHIFT MUTATION; GENE DELETION; GENE SILENCING; GENETIC PREDISPOSITION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; LOW DRUG DOSE; META ANALYSIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTICARCINOGENIC AGENTS; ASPIRIN; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; HUMANS; MICROSATELLITE INSTABILITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84870800053     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000341892     Document Type: Conference Paper

References (22)

1. Lynch HT, Krush AJ: Cancer family 'G' revisited:1895-1970. Cancer 1971; 27: 1505-1511.
2. Vasen HF, Moslein G, Alonso A, Bernstein I,Bertario L, Blanco I, Burn J, Capella G, EngelC, Frayling I, Friedl W, Hes FJ, Hodgson S,Mecklin JP, Moller P, Nagengast F, Parc Y,Renkonen-Sinisalo L, Sampson JR, StormorkenA, Wijnen J: Guidelines for the clinicalmanagement of Lynch syndrome (hereditarynon-polyposis cancer). J Med Genet2007; 44: 353-362.
3. Peltomaki P, Aaltonen LA, Sistonen P, PylkkanenL, Mecklin J-P, Jarvinen H, Green JS,Jass JR, Weber JL, Leach FS, Petersen GM,Hamilton SR, De la Chapelle A, Vogelstein B:Genetic mapping of a locus predisposing tohuman colorectal cancer. Science 1993; 260:810-819.
4. Fishel R, Lescoe MK, Rao MRS, CopelandNG, Jenkins NA, Garber J, Kane M, KolodnerR: The human mutator gene homologMSH2 and its association with hereditarynonpolyposis colon cancer. Cell 1993; 75:1027-1038.
5. Hampel H, Frankel WL, Martin E, Arnold M,Khanduja K, Kuebler P, Clendenning M, SotamaaK, Prior T, Westman JA, Panescu J, Fix D,Lockman J, LaJeunesse J, Comeras I, de la ChapelleA: Feasibility of screening for Lynch syndromeamong patients with colorectal cancer.J Clin Oncol 2008; 26: 5783-5788.
6. Wheeler JMD, Loukola A, Aaltonen LA,Mortensen NJM, Bodmer WF: The role ofhypermethylation of the hMLH1 promoterregion in HNPCC versus MSI+ sporadiccolorectal cancers. J Med Genet 2000; 37:588-592.
7. Ligtenberg MJ, Kuiper RP, Chan TL, GoossensM, Hebeda KM, Voorendt M, Lee TY,Bodmer D, Hoenselaar E, Hendriks-CornelissenSJ, Tsui WY, Kong CK, Brunner HG,van Kessel AG, Yuen ST, van Krieken JH,Leung SY, Hoogerbrugge N: Heritable somaticmethylation and inactivation of MSH2in families with Lynch syndrome due to deletionof the 3-exons of TACSTD1. Nat Genet2009; 41: 112-117.
8. Clendenning M, Senter L, Hampel H, RobinsonKL, Sun S, Buchanan D, Walsh MD,Nilbert M, Green J, Potter J, Lindblom A, dela Chapelle A: A frame-shift mutation ofPMS2 is a widespread cause of Lynch syndrome.J Med Genet 2008; 45: 340-345.
9. Domingo E, Laiho P, Ollikainen M, Pinto M,Wang L, French AJ, Westra J, Frebourg T, EspinE, Armengol M, Hamelin R, YamamotoH, Hofstra RMW, Seruca R, Lindblom A,Peltomaki P, Thibodeau SN, Aaltonen LA,Schwartz S Jr: BRAF screening as a low-costeffective strategy for simplifying HNPCCgenetic testing. J Med Genet 2004; 41: 664-668.
10. Dinh TA, Rosner BI, Atwood JC, Boland CR,Syngal S, Vasen HF, Gruber SB, Burt RW:Health benefits and cost-effectiveness of primarygenetic screening for Lynch syndromein the general population. Cancer Prev Res(Phila) 2011; 4: 9-22.
11. Schwitalle Y, Kloor M, Eiermann S, LinnebacherM, Kienle P, Knaebel HP, TariverdianM, Benner A, von Knebel Doeberitz M: Immuneresponse against frameshift-inducedneopeptides in HNPCC patients and healthyHNPCC mutation carriers. Gastroenterology2008; 134: 988-997.
12. Kloor M, Michel S, Buckowitz B, RuschoffJ, Buttner R, Holinski-Feder E, DippoldW, Wagner R, Tariverdian M, Benner A,Schwitalle Y, Kuchenbuch B, von KnebelDoeberitz M: Beta2-microglobulin mutationsin microsatellite unstable colorectal tumors.Int J Cancer 2007; 121: 454-458.
13. Ribic CM, Sargent DJ, Moore MJ, ThibodeauSN, French AJ, Goldberg RM, Hamilton SR,Laurent-Puig P, Gryfe R, Shepherd LE, Tu D,Redston M, Gallinger, S: Tumor microsatellite-instability status as a predictor of benefitfrom fluorouracil-based adjuvant chemotherapyfor colon cancer. N Engl J Med 2003;349: 247-257.
14. Burn J, Bishop DT, Chapman PD, Elliott F,Bertario L, Dunlop MG, Eccles D, Ellis A,Evans DG, Fodde R, Maher ER, Moslein G,Vasen HF, Coaker J, Phillips RK, Bulow S,Mathers JC: A randomized placebo-controlledprevention trial of aspirin and/or resistantstarch in young people with familialadenomatous polyposis. Cancer Prev Res(Phila) 2011; 4: 655-665.
15. Kune GA, Kune S, Watson LF: Colorectalcancer risk, chronic illnesses, operations,and medications: case control results fromthe Melbourne Colorectal Cancer Study.Cancer Res 1988; 48: 4399-4404.
16. Cuzick J, Otto F, Baron JA, Brown PH, BurnJ, Greenwald P, Jankowski J, La Vecchia C,Meyskens F, Senn HJ, Thun M: Aspirin andnon-steroidal anti-inflammatory drugs forcancer prevention: an international consensusstatement. Lancet Oncol 2009; 10: 501-507.
17. Burn J, Bishop DT, Mecklin JP, Macrae F,Moslein G, Olschwang S, Bisgaard ML, RamesarR, Eccles D, Maher ER, Bertario L,Jarvinen HJ, Lindblom A, Evans DG, LubinskiJ, Morrison PJ, Ho JW, Vasen HF, Side L,Thomas HJ, Scott RJ, Dunlop M, Barker G,Elliott F, Jass JR, Fodde R, Lynch HT, MathersJC: Effect of aspirin or resistant starch oncolorectal neoplasia in the Lynch syndrome.N Engl J Med 2008; 359: 2567-2578.
18. Burn J, Gerdes AM, Macrae F, Mecklin JP,Moeslein G, Olschwang S, Eccles D, EvansDG, Maher ER, Bertario L, Bisgaard ML,Dunlop MG, Ho JW, Hodgson SV, LindblomA, Lubinski J, Morrison PJ, Murday V, RamesarR, Side L, Scott RJ, Thomas HJ, VasenHF, Barker G, Crawford G, Elliott F, MovahediM, Pylvanainen K, Wijnen JT, Fodde R,Lynch HT, Mathers JC, Bishop DT: Longtermeffect of aspirin on cancer risk in carriersof hereditary colorectal cancer: an analysisfrom the CAPP2 randomised controlledtrial. Lancet 2011; 378: 2081-2087.
19. Flossmann E, Rothwell PM: Effect of aspirinon long-term risk of colorectal cancer: consistentevidence from randomised and observationalstudies. Lancet 2007; 369: 1603-1613.
20. Rothwell PM, Wilson M, Elwin CE, NorrvingB, Algra A, Warlow CP, Meade TW:Long-term effect of aspirin on colorectalcancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet2010; 376: 1741-1750.
21. Rothwell PM, Wilson M, Price JF, Belch JF,Meade TW, Mehta Z: Effect of daily aspirinon risk of cancer metastasis: a study of incidentcancers during randomised controlledtrials. Lancet 2012; 379: 1591-1601.
22. Chan AT, Ogino S, Fuchs CS: Aspirin useand survival after diagnosis of colorectalcancer. JAMA 2009; 302: 649-658.